vs
GENMAB A/S（GMAB）与Primerica, Inc.（PRI）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是Primerica, Inc.的1.1倍（$925.0M vs $853.7M），GENMAB A/S净利率更高（36.3% vs 23.1%，领先13.2%），GENMAB A/S同比增速更快（18.7% vs 11.0%）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Primerica, Inc.是一家采用多层次营销模式的金融服务机构，业务覆盖美国与加拿大市场，主要面向当地中等收入家庭提供保险、投资等多元化金融产品，满足客户的风险保障与差异化财富管理需求。
GMAB vs PRI — 直观对比
营收规模更大
GMAB
是对方的1.1倍
$853.7M
营收增速更快
GMAB
高出7.7%
11.0%
净利率更高
GMAB
高出13.2%
23.1%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $853.7M |
| 净利润 | $336.0M | $197.0M |
| 毛利率 | 93.8% | — |
| 营业利润率 | 38.9% | 28.9% |
| 净利率 | 36.3% | 23.1% |
| 营收同比 | 18.7% | 11.0% |
| 净利润同比 | 65.5% | 17.9% |
| 每股收益（稀释后） | $5.42 | $6.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABPRI
| Q4 25 | — | $853.7M | ||
| Q3 25 | — | $839.9M | ||
| Q2 25 | $925.0M | $793.3M | ||
| Q1 25 | — | $804.8M | ||
| Q4 24 | — | $768.8M | ||
| Q3 24 | — | $774.1M | ||
| Q2 24 | $779.0M | $803.4M | ||
| Q1 24 | — | $742.8M |
净利润GMABPRI
| Q4 25 | — | $197.0M | ||
| Q3 25 | — | $206.8M | ||
| Q2 25 | $336.0M | $178.3M | ||
| Q1 25 | — | $169.1M | ||
| Q4 24 | — | $167.1M | ||
| Q3 24 | — | $164.4M | ||
| Q2 24 | $203.0M | $1.2M | ||
| Q1 24 | — | $137.9M |
毛利率GMABPRI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 93.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 96.4% | 98.0% | ||
| Q1 24 | — | 98.2% |
营业利润率GMABPRI
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 32.3% | ||
| Q2 25 | 38.9% | 29.6% | ||
| Q1 25 | — | 27.5% | ||
| Q4 24 | — | 64.7% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | 30.3% | 1.0% | ||
| Q1 24 | — | 24.1% |
净利率GMABPRI
| Q4 25 | — | 23.1% | ||
| Q3 25 | — | 24.6% | ||
| Q2 25 | 36.3% | 22.5% | ||
| Q1 25 | — | 21.0% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | 26.1% | 0.1% | ||
| Q1 24 | — | 18.6% |
每股收益（稀释后）GMABPRI
| Q4 25 | — | $6.11 | ||
| Q3 25 | — | $6.35 | ||
| Q2 25 | $5.42 | $5.40 | ||
| Q1 25 | — | $5.05 | ||
| Q4 24 | — | $4.92 | ||
| Q3 24 | — | $4.83 | ||
| Q2 24 | $3.13 | $0.03 | ||
| Q1 24 | — | $3.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $756.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $2.4B |
| 总资产 | $6.5B | $15.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABPRI
| Q4 25 | — | $756.2M | ||
| Q3 25 | — | $644.9M | ||
| Q2 25 | $1.3B | $621.2M | ||
| Q1 25 | — | $625.1M | ||
| Q4 24 | — | $687.8M | ||
| Q3 24 | — | $550.1M | ||
| Q2 24 | $622.0M | $627.3M | ||
| Q1 24 | — | $593.4M |
股东权益GMABPRI
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $5.3B | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | $4.4B | $2.1B | ||
| Q1 24 | — | $2.2B |
总资产GMABPRI
| Q4 25 | — | $15.0B | ||
| Q3 25 | — | $14.8B | ||
| Q2 25 | $6.5B | $14.8B | ||
| Q1 25 | — | $14.6B | ||
| Q4 24 | — | $14.6B | ||
| Q3 24 | — | $14.8B | ||
| Q2 24 | $5.6B | $14.6B | ||
| Q1 24 | — | $14.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $338.2M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | — |
| 自由现金流率自由现金流/营收 | 35.4% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 1.04× | 1.72× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GMABPRI
| Q4 25 | — | $338.2M | ||
| Q3 25 | — | $202.9M | ||
| Q2 25 | $349.0M | $162.6M | ||
| Q1 25 | — | $197.5M | ||
| Q4 24 | — | $270.6M | ||
| Q3 24 | — | $207.3M | ||
| Q2 24 | $438.0M | $173.3M | ||
| Q1 24 | — | $210.9M |
自由现金流GMABPRI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $327.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $430.0M | — | ||
| Q1 24 | — | — |
自由现金流率GMABPRI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 55.2% | — | ||
| Q1 24 | — | — |
资本支出强度GMABPRI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | — | — |
现金转化率GMABPRI
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | 1.04× | 0.91× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | 1.62× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | 2.16× | 147.98× | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
